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ABSTRACT 33 
Background: Early recognition of dementia would allow patients and their families to receive 34 
care earlier in the disease process, potentially improving care management and patient outcomes, 35 
yet nearly half of patients with dementia are undiagnosed.  36 
Objective: To develop and validate an electronic health record (EHR)-based tool to help detect 37 
patients with unrecognized dementia (eRADAR). 38 
Design: Retrospective cohort study. 39 
Setting: Kaiser Permanente Washington (KPWA), an integrated healthcare delivery system. 40 
Participants: 16,665 visits among 4,330 participants in the Adult Changes in Thought (ACT) 41 
study, who undergo a comprehensive process to detect and diagnose dementia every two years 42 
and have linked KPWA EHR data, divided into development (70%) and validation (30%) 43 
samples.  44 
Measurements: EHR predictors included demographics, medical diagnoses, vital signs, 45 
healthcare utilization and medications within the previous two years. Unrecognized dementia 46 
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was defined as detection in ACT prior to documentation in the KPWA EHR (i.e., lack of 47 
dementia or memory loss diagnosis codes or dementia medication fills). 48 
Results: 1,015 ACT visits resulted in a diagnosis of incident dementia, of which 498 (49%) were 49 
unrecognized in the KPWA EHR. The final 31-predictor model included markers of dementia-50 
related symptoms (e.g., psychosis diagnoses, anti-depressant fills), healthcare utilization pattern 51 
(e.g., emergency department visits); and dementia risk factors (e.g., cerebrovascular disease, 52 
diabetes). Discrimination was good in the development (c statistic, 0.78; 95% CI: 0.76, 0.81) and 53 
validation (0.81; 0.78, 0.84) samples, and calibration was good based on plots of predicted vs. 54 
observed risk. If patients with scores in the top 5% were flagged for additional evaluation, we 55 
estimate that 1 in 6 would have dementia. 56 
Conclusion: eRADAR uses existing EHR data to detect patients who may have unrecognized 57 
dementia with good accuracy.    58 
 59 
Keywords: dementia, decision support techniques, early diagnosis  60 
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INTRODUCTION 61 
There are currently 5.8 million people in the U.S. living with dementia, approximately 62 
half of whom have never received a diagnosis.1,2 Many potential benefits of earlier dementia 63 
recognition have been proposed.3-5 Reversible and treatable causes of cognitive impairment can 64 
be identified. Evidence-based collaborative care models can be implemented to enable better 65 
management of patient symptoms,6,7 which could lower risk of emergency department (ED) 66 
visits and hospitalizations.8 Patients may choose to start cholinesterase inhibitors, which may 67 
improve symptoms in some patients.9 Patients can be engaged in planning for their future, and 68 
caregivers can be provided with education and support, which can reduce stress and improve 69 
well-being.10,11 Interventions can be implemented to minimize risky behaviors such as 70 
driving.12,13  71 
There are also potential harms of earlier detection of dementia. These include 72 
anxiety/depression; stigma/social isolation; loss of independence such as driving privileges; and 73 
negative financial consequences such as denial of long-term care insurance. 3,4 74 
Given the tension between potential benefits and harms, agencies such as the U.S. 75 
Preventive Services Task Force and the U.K. National Institute for Health Care Excellence do 76 
not recommend for or against routine screening for dementia.14,15 However, other organizations 77 
such as the Alzheimer’s Association and the Gerontological Society of America advocate for 78 
early detection and diagnosis so that patients and families can be provided with adequate support 79 
and education throughout the disease process.5,16  80 
There are many barriers to early dementia diagnosis in the primary care setting, including 81 
lack of evidence from clinical trials and lack of demand from patients, caregivers and 82 
clinicians.4,5,17-20 Insufficient time is often identified as the single most important factor by 83 
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primary care physicians.2,18,19,21,22 Several studies also have identified the need for standardized 84 
tools and information technology resources to address this barrier and support earlier recognition 85 
of Alzheimer’s and dementia in primary care.2,17,22 86 
We have previously found that patients with unrecognized dementia often have ‘warning 87 
signs’ (i.e., markers of high risk) in the electronic health record (EHR) such as history of stroke, 88 
recent ED visits and “no shows” for scheduled clinic visits.23 The goal of this study was to 89 
develop and validate an EHR-based prediction tool to identify patients at high risk of 90 
unrecognized dementia, which we call the EHR Risk of Alzheimer’s and Dementia Assessment 91 
Rule (eRADAR).    92 
 93 
METHODS 94 
Setting 95 
The setting for this study is Kaiser Permanente Washington (KPWA, formerly Group 96 
Health Cooperative). KPWA is a not-for-profit health plan that provides medical coverage and 97 
care to more than 710,000 members in Washington State, including nearly 93,000 Medicare 98 
Advantage beneficiaries. The two-year retention rate for members age 65 years or older is about 99 
85%. KPWA utilizes the Epic EHR, which was fully deployed at all KPWA clinics and specialty 100 
centers as of November 2005. Before this time, healthcare data were recorded and maintained in 101 
a variety of other electronic databases, which remain available and have been widely used for 102 
research. Diagnosis and procedure data are available dating back to the early 1990s, while 103 
electronic prescription data are available back to 1977. 104 
 105 
Study population 106 
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Our study population was drawn from the Adult Changes in Thought (ACT) study, an 107 
ongoing, prospective cohort study of risk factors for Alzheimer’s disease and dementia that is 108 
embedded within KPWA.24 In 1994, ACT enrolled a random sample of Seattle-area KPWA 109 
members who were at least 65 years old, community-dwelling and did not have dementia. 110 
Additional enrollment waves have been added periodically to maintain the cohort size. ACT 111 
study participants are 89% non-Hispanic white and have a median (interquartile range) of 14 (12, 112 
16) years of education.   113 
 114 
Diagnosis of dementia 115 
Every 2 years, ACT participants undergo cognitive screening with the Cognitive Abilities 116 
Screening Instrument (CASI).25 Those with abnormal results undergo in-depth evaluation, 117 
including a neuropsychological test battery, physical examination including neurologic 118 
assessment, and detailed review of medical records.  If no recent imaging results are available, 119 
imaging may be ordered. A multidisciplinary consensus committee reviews all available data and 120 
assigns diagnoses based on standard research criteria.26,27  121 
This study used the ACT visit as the unit of analysis to take advantage of repeated 122 
dementia assessments in the ACT cohort. We classified participants’ status at each ACT follow-123 
up visit as 1) no dementia, 2) recognized dementia or 3) unrecognized dementia. Specifically, we 124 
classified dementia as ‘recognized’ if the KPWA EHR included any diagnosis codes for 125 
dementia or memory complaints or dementia medication fills during the two years prior to the 126 
ACT visit date and as ‘unrecognized’ if none of these criteria were met. We included diagnosis 127 
codes for memory complaints in our ‘recognized’ dementia group because our goal was to 128 
develop a tool to help clinicians identify patients who were not already recognized as being ‘at 129 
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risk.’ We excluded baseline visits because individuals with dementia at baseline were not 130 
enrolled in ACT. We also excluded visits at which participants were not enrolled in KPWA for 131 
the prior two years (because EHR predictors might be incomplete) and visits after KPWA’s 132 
transition to International Classification of Diseases 10 (ICD-10) coding (10/1/2015, for data 133 
consistency). Our final sample included 16,655 study visits among 4,330 patients.    134 
 135 
Potential EHR predictors of unrecognized dementia 136 
A wide range of potential EHR predictors of unrecognized dementia were considered. 137 
Some predictors were informed by our prior work23 and a priori hypotheses regarding factors that 138 
might be associated with increased risk of undiagnosed dementia (such as receiving care for 139 
dementia-related symptoms, missing clinic visits and poor medication adherence). Other 140 
predictors were based on well-established algorithms for administrative data.28,29 The period of 141 
assessment for most predictors was the two years preceding the ACT visit. Height, weight and 142 
blood pressure were not captured in the EHR until 2003; therefore, we used the most recently 143 
recorded value from either the EHR or the ACT visit during the preceding three years to 144 
minimize missing data. Predictors were grouped into the broad categories of demographics, 145 
diagnoses, vital signs, healthcare utilization and medication-related predictors. In addition, to 146 
maximize the clinical utility of the tool, we classified predictors as being more or less easily 147 
obtainable in most medical systems. A complete list of predictors considered is included in 148 
Supplementary Table S1. 149 
 150 
More easily obtainable EHR predictors 151 
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a) Demographics: We considered age, gender, and race/ethnicity as potential demographic 152 
predictors. Race/ethnicity was dichotomized as non-Hispanic white versus other because the 153 
proportion of ACT participants with nonwhite race/ethnicity is small (10%).  154 
b) Diagnoses. We identified comorbid medical conditions using a code list drawn primarily 155 
from ICD-9 codes recommended by Elixhauser or Charlson.28,29 A total of 31 specific conditions 156 
were considered including hypertension, myocardial infarction, congestive heart failure, 157 
cerebrovascular disease, diabetes, alcohol dependence/abuse, psychoses, depression, traumatic 158 
brain injury, tobacco use disorder, atrial fibrillation and gait abnormality.  159 
c) Vital signs. Height, weight and blood pressure were determined based on the most 160 
recently recorded EHR value. Height and weight were used to calculate body mass index (BMI, 161 
kg/m2), which was classified using standard cut-points: underweight (<18.5), normal (18.5-24.9), 162 
overweight (25.0-29.9) or obese (≥30). Systolic and diastolic blood pressure (SBP, DBP, mm 163 
Hg) were categorized using standard clinical cut-points: low (≤90 SBP or ≤60 DBP), normal (90-164 
139 SBP and 60-89 DBP), high (140-180 SBP or 90-110 DBP) or very high (>180 SBP or >110 165 
DBP). For <1% of visits, no information on blood pressure or BMI was available in the 166 
preceding three years. In these cases, we imputed values for the missing data using fully 167 
conditional specification methods available in SAS, version 9.4 (SAS Institute, Inc., Cary, NC). 168 
d) Healthcare utilization. We classified the number and type of interactions with the 169 
healthcare system including outpatient, ED and urgent care visits, and hospitalizations. In 170 
addition, we identified visits and hospitalizations for accidents/injuries (which could reflect 171 
dementia-related challenges with daily activities) and we determined whether patients had 172 
received specialty services that might be related to symptoms of dementia such as social work; 173 
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home health; physical therapy; mental health; speech, language and learning evaluation (the 174 
primary route for cognitive or neuropsychologic testing within KPWA); or neurology.  175 
e) Medication-related predictors. We used electronic pharmacy dispensing data to examine 176 
fills for medications that could be related to dementia symptoms including tricyclic and non-177 
tricyclic (TCA) anti-depressants and sedative/hypnotic medications.  178 
 179 
Less easily obtainable EHR predictors 180 
a) Healthcare utilization. We created a separate variable for hospitalizations/ED visits 181 
related to ambulatory care sensitive (ACS) conditions (which are often considered a marker of 182 
potentially avoidable admissions).30 In addition, we drew on KPWA scheduling and clinical 183 
databases to identify “no shows” for scheduled clinic visits. 184 
b) Medication-related predictors. We examined medication adherence for three categories of 185 
commonly prescribed medications (oral hypoglycemic agents, antihypertensive medications and 186 
statins). Non-adherence was defined as <80 percent of days covered (PDC), consistent with 187 
national quality measures.31 Individuals who did not take these medications or had ≥80% PDC 188 
were classified as adherent. Four variables were created to reflect non-adherence for each class 189 
separately as well as overall. 190 
 191 
Analytic approach 192 
Logistic regression with LASSO (least absolute shrinkage and selection operator) 193 
penalty32 was used to identify EHR predictors of unrecognized dementia versus no dementia and 194 
to build a prediction model to estimate the probability of unrecognized dementia for each person 195 
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at each visit. Visits classified as ‘recognized dementia’ were excluded since our goal was to 196 
identify patients with unrecognized dementia to target for further evaluation.  197 
The LASSO penalization factor selects predictors by shrinking coefficients for weaker 198 
predictors toward zero, excluding predictors with estimated zero coefficients from the final 199 
prediction model.  Simulation studies suggest that LASSO leads to less overfitting and more 200 
accurate prediction models than more traditional methods such as stepwise selection.33   201 
For model development and validation, we randomly divided the data into training (70%) 202 
and test (30%) samples. To minimize overfitting, we used the training sample to select the 203 
LASSO tuning parameter 𝜆𝜆 that minimized the binomial deviance via 10-fold cross validation. 204 
We generated the final model by fitting the logistic regression with LASSO to the entire training 205 
sample using the selected tuning parameter. We implemented the above procedure using the 206 
glmnet package (version 2.0.16) in R (version 3.4.4). We assessed calibration and discrimination 207 
performance in the training and test samples graphically34 and through computation of c-statistics 208 
(area under the receiver operating characteristic [ROC] curve [AUC] for a binary outcome). 209 
Confidence intervals for AUC estimates were calculated via bootstrap with 10,000 replications. 210 
Two models were created. We first considered the full set of 64 predictors described in 211 
the preceding section. Next, to maximize the potential portability of the model into other 212 
healthcare systems, we rebuilt the model after excluding predictors likely to be difficult to obtain 213 
in some settings (specifically, variables based on ACS conditions, no shows and medication non-214 
adherence).  215 
For sensitivity analyses, we explored alternative modeling using other machine learning 216 
methods such as ridge regression, decision trees, random forests, gradient boosting, support 217 
vector machines, and neural networks.35 We also estimated another prediction model using all 218 
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dementia cases (both recognized and unrecognized) and compared its performance with that of 219 
our primary model.  220 
 221 
Role of the funding source 222 
Funders were not involved with the design, conduct or reporting of results.  223 
 224 
IRB approval  225 
All study procedures were approved by Institutional Review Boards at the University of 226 
California, San Francisco and Kaiser Permanente Washington and by the San Francisco Veterans 227 
Affairs Research & Development Committee.  228 
 229 
RESULTS 230 
 Our final sample included 16,655 ACT visits among 4,330 patients. At the patient level, 231 
23.4% developed dementia, 24.7% died, 7.1% withdrew from ACT, 34.6% reached the end of 232 
our study period without developing dementia, 4.7% disenrolled from KPWA, and 5.5% were 233 
lost to follow-up (e.g., did not return for their biennial visits). At the visit level, 1,015 visits 234 
resulted in an ACT dementia diagnosis, of which about half (n=498) were unrecognized in the 235 
EHR (overall, 49%; 1996-2000, 54%; 2001-2005: 59%; 2006-2010: 46%; 2011-2015: 38%). The 236 
mean age of participants over the visits was 80 years, and 60% of visits were in female 237 
participants. Table 1 shows the prevalence of selected predictors overall and stratified by 238 
dementia status at the time of the visit. Data for all predictors considered are included in 239 
Supplementary Table S1. 240 
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 The final coefficients for the restricted and full models are shown in Table 2. The 241 
restricted model included a combination of demographics (older age, male sex); medical 242 
diagnoses (e.g., psychoses, diabetes, congestive heart failure, cerebrovascular disease, gait 243 
abnormalities); healthcare utilization (e.g., emergency department or speech therapy visits); vital 244 
signs (e.g., underweight); and medication-related predictors (e.g., antidepressant fills other than 245 
TCAs) (Figure 1). The restricted model c-statistic was 0.78 (95% CI: 0.76, 0.81) in the training 246 
sample and 0.81 (0.78, 0.84) in the test sample. The c-statistic in the test sample was consistent 247 
over time (1996-2000: 0.83 [0.75, 0.90]; 2001-2005: 0.78 [0.73, 0.83]; 2006-2010: 0.79 [0.72, 248 
0.85]; 2011-2015: 0.83 [0.76, 0.90]). 249 
In the full model, most predictors and coefficient values were similar to those for the 250 
restricted model (Table 2). The key differences were that some variables were no longer included 251 
(diabetes, lymphoma, or depression diagnoses; home health visits; sedative/hypnotic medication 252 
fills) while others were added (clinic no shows; ACS hospitalizations and ED visits; non-253 
adherence to hypoglycemic, antihypertensive or statin medications). The full model c-statistic 254 
was 0.79 (0.65, 0.81) in the training sample and 0.81 (0.77, 0.84) in the test sample.  255 
Figure 2 shows the performance characteristics of the final restricted model in the 256 
training and test samples (see Supplementary Figure S1 for full model). The ROC curves and 257 
AUC estimates (Figure 2a) suggest good discrimination between patients with no dementia and 258 
unrecognized dementia. The calibration plots (Figure 2b) suggest reasonable correspondence 259 
between observed and predicted risk across the full range of scores. Overall, there is no evidence 260 
of overfitting based on a comparison of discrimination and calibration between training and test 261 
samples.  262 
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Table 3 shows performance characteristics of the final restricted model when using 263 
different predicted risk cut-offs for classifying subjects as having unrecognized dementia at a 264 
given visit (see Supplementary Table S3 for full model). For example, using a 95th percentile cut-265 
off in the training sample yielded a sensitivity of 22%, specificity of 96%, positive predictive 266 
value (PPV) of 16% and negative predictive value (NPV) of 98% in the test sample. This 267 
suggests that, if the top 5% of patients were evaluated, 16% (roughly 1 in 6 patients) would be 268 
predicted to have unrecognized dementia. In contrast, the overall visit-level prevalence of 269 
unrecognized dementia was 3%.  270 
Exploration of other machine learning methods did not produce better performing models 271 
compared to our primary approach (c-statistics from restricted model test sample: ridge 272 
regression: 0.81; random forest: 0.76; boosting: 0.81; SVM: 0.67; neural network: 0.64). Using 273 
all dementia cases (rather than restricting to unrecognized dementia) also did not improve 274 
performance (restricted model: 0.80; full model: 0.80).  275 
 276 
DISCUSSION 277 
 In this study of more than 16,000 visits between 1995 and 2015 among 4,330 older adults 278 
from the ACT study,24 we found that about half of participants who were diagnosed with incident 279 
dementia through ACT appeared to be unrecognized by the healthcare system. The proportion 280 
who were unrecognized declined slightly over time but was high in all study years. These 281 
findings are consistent with prior studies2,5,17,36 and suggest that under-recognition of dementia 282 
remains a major concern. 283 
 We also found that information that is readily available in the EHR can be used to detect 284 
patients who may have unrecognized dementia with good accuracy. Key predictors included 285 
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patterns of health care utilization, dementia-related symptoms, and dementia risk factors. We 286 
also found that variables such as poor medication adherence and clinic visit ‘no shows’ were 287 
associated with increased risk of unrecognized dementia, although adding these more novel 288 
predictors (which may be difficult to extract in some EHRs) did not improve prognostic accuracy 289 
compared to a model that only considered more easily extractable predictors. This may be 290 
explained by correlations between predictors that enabled substitutions without loss of 291 
prognostic performance. Model accuracy was slightly better in the test sample, suggesting that 292 
over-fitting is not a concern.  293 
We also examined the trade-offs between sensitivity and PPV to understand the potential 294 
impact of implementing eRADAR in clinical practice.  If the 85th percentile were set as a 295 
threshold for recommending follow-up evaluation (for example, a phone or office visit to assess 296 
memory), sensitivity would be 47% and PPV 10%—that is, we would detect nearly half of 297 
patients with undiagnosed dementia, and about 1 in 10 people evaluated would have dementia. 298 
For context, 12% of screening mammograms are interpreted as abnormal, with 87% sensitivity 299 
and 4% PPV (~23 people evaluated with diagnostic mammograms and/or biopsies to detect 1 300 
breast cancer).37  For fecal immunochemical testing (FIT), a recent community-based study 301 
found 74% sensitivity and 2% PPV using a 20 mcg/g cut-off (~52 people evaluated via 302 
colonoscopy to detect 1 case of colorectal cancer).38  Thus, eRADAR’s performance is 303 
comparable to other common clinical procedures.  304 
To our knowledge, this is the first study to develop a risk prediction model that uses 305 
readily available EHR data to detect patients with unrecognized dementia. Most existing models 306 
focus on predicting future risk of developing dementia.39,40 For example, our Dementia 307 
Screening Indicator41 is a simple tool designed to identify older adults with an elevated risk of 308 
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developing dementia within 6 years. These tools may be optimal for identifying patients to target 309 
for risk reduction interventions, rather than detecting patients with unrecognized dementia, since 310 
they focus on predicting future risk.  311 
Several other tools have recently been developed that use text-based EHR data to more 312 
accurately differentiate between patients with and without dementia.42-44 For example, Amra et 313 
al.42 developed an algorithm that uses EHR text words (such as “cognitive impairment,” 314 
“impaired memory” or “difficulty concentrating”) to discriminate between patients with and 315 
without dementia. A limitation is that many clinical settings may not have the resources or 316 
technical capabilities to extract information from free text fields such as clinic notes. Also, such 317 
approaches are likely to identify patients who are already known by clinicians to potentially have 318 
dementia. In contrast, our tool is designed to identify patients with dementia who have not yet 319 
been recognized by their clinicians.  320 
Another limitation of prior studies is that most models were developed to predict 321 
diagnosed dementia and have assumed that results would apply to undiagnosed dementia.43-45  322 
However, our prior work suggests that patients with undiagnosed dementia often have values that 323 
fall in between patients with diagnosed dementia and those without dementia.23  Thus, models 324 
that are optimized to predict diagnosed dementia may be less accurate for identifying 325 
unrecognized dementia cases.  326 
This study has several strengths. We examined a large sample that included 16,655 visits 327 
among 4,330 patients and nearly 500 cases of unrecognized dementia. In addition, we examined 328 
a wide range of potential EHR predictors based on a conceptual model developed a priori.  329 
We also acknowledge several limitations. 1) Our definition of unrecognized dementia 330 
relied on EHR diagnosis codes and medication fills. It is possible that some clinicians were 331 
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aware of a patient’s dementia status but did not code or prescribe medications for it, although our 332 
pilot work confirmed that 90% of cases were unrecognized based on detailed chart review.23 2) 333 
Generalizability may be limited given our sample, which was primarily white, well-educated, 334 
English speaking, and from one healthcare system in one region of the country. Patterns of 335 
healthcare utilization, access to services and medication compliance may differ in those with 336 
lower socioeconomic status or education levels, and results may not be readily transported 337 
outside the U.S. where practices for screening, diagnosis and coding of dementia may differ. 3) 338 
If implemented, the model would not identify all patients with undiagnosed dementia, and those 339 
not identified would not be targeted for further evaluation. 4) Some predictors in the final model 340 
do not make intuitive sense; for example, solid tumor without metastasis is associated with a 341 
lower risk of undiagnosed dementia. These patients may be more likely to receive a diagnosis 342 
due to greater interaction with the health care system. We also note that prognostic models can 343 
be accurate even when counterintuitive. 5) There are other predictors that we did not consider in 344 
this model, such as antipsychotic and anticholinergic medications, non-compliance with other 345 
types of medications, laboratory test results, and hospital visits with delirium or intensive care 346 
unit stays. We also did not use techniques such as natural language processing to examine 347 
clinical note fields. Future studies should determine whether the accuracy of our model is 348 
improved by including additional predictors or using alternative techniques. It also would be of 349 
great value to validate our model in new databases or through a prospective validation study 350 
within a real-world population. 351 
We recognize that there are many barriers to dementia diagnosis,5,17,19,21,46 and that the 352 
idea of applying a tool such as eRADAR to detect cases of unrecognized dementia may raise 353 
concerns among some patients or clinicians. For example, one study found that nearly half of 354 
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patients with positive dementia screens declined further evaluation.47 Implementing an EHR-355 
based tool will require careful design and should incorporate input and guidance from patients, 356 
caregivers and clinicians to address barriers and minimize the potential for unintended adverse 357 
consequences. It is likely that both clinicians and patients will need enhanced support and 358 
resources if more cases of dementia are detected.  359 
In summary, we have developed and internally validated eRADAR, a tool that uses 360 
readily available EHR data to identify patients who may have unrecognized dementia with good 361 
accuracy. Future studies should explore the optimal approach to implementing eRADAR, which 362 
could involve applying it at the point of care (e.g. an EHR-based alert that could fire during a 363 
clinic visit) or providing risk score information to clinical teams to support proactive outreach to 364 
patients outside of scheduled visits.48 Future studies should assess not only benefits but also 365 
potential downstream costs or burdens to the patient, family and healthcare system.  366 
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FIGURE LEGENDS 509 
Figure 1. Key predictors of undiagnosed dementia in the electronic health record Risk of 510 
Alzheimer’s and Dementia Assessment Rule (eRADAR) included dementia risk factors, 511 
dementia-related symptoms, and healthcare utilization patterns.  512 
 513 
Figure 2. The performance characteristics of the final restricted eRADAR model are shown for 514 
the training sample (left panels) and test sample (right panels). Figure 2a shows the receiver 515 
operating characteristic (ROC) curves with c-statistics. The ROC curve plots the sensitivity (true 516 
positive rate) against 1 - specificity (false positive rate) for consecutive cutoffs for the probability 517 
of unrecognized dementia. The c-statistic reflects the area under the ROC curve (AUC), with 518 
values of 0.5 reflecting prediction no better than chance and 1 reflecting perfect prediction. 519 
Figure 2b provides a graphical assessment of calibration (i.e., the extent to which predicted risk 520 
matches actual risk). The mean predicted probability of unrecognized dementia is plotted against 521 
the observed proportion of unrecognized dementia cases by quintiles of predicted risk. The figure 522 
shows close alignment between observed and predicted values (ideal calibration aligns with the 523 
45-degree line). The histogram at the bottom shows the distribution of the predicted risks. Most 524 
visits had relatively low predicted risk of undiagnosed dementia (<5%). Supplementary Figure 525 
S1 provides similar figures for the model that considered the full set of predictors.  526 
 527 
Supplementary Figure S1. The performance characteristics of the final full eRADAR model are 528 
shown for the training sample (left panels) and test sample (right panels). Figure 2a shows the 529 
receiver operating characteristic (ROC) curves with c-statistics. The ROC curve plots the 530 
sensitivity (true positive rate) against 1 - specificity (false positive rate) for consecutive cutoffs 531 
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for the probability of unrecognized dementia. The c-statistic reflects the area under the ROC 532 
curve (AUC), with values of 0.5 reflecting prediction no better than chance and 1 reflecting 533 
perfect prediction. Figure 2b provides a graphical assessment of calibration (i.e., the extent to 534 
which predicted risk matches actual risk). The mean predicted probability of unrecognized 535 
dementia is plotted against the observed proportion of unrecognized dementia cases by quintiles 536 
of predicted risk. The figure shows close alignment between observed and predicted values (ideal 537 
calibration aligns with the 45-degree line). The histogram at the bottom shows the distribution of 538 
the predicted risks. Most visits had relatively low predicted risk of undiagnosed dementia (<5%).   539 
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Table 1. Prevalence of Electronic Health Record (EHR) Predictors Included in Final 540 
Models by Visit Status 541 
 542 
  Visit Status* 
EHR Predictors Overall 
(n=16,655) 
No 
dementia 
(n=15,640) 
Unrecognized 
dementia  
(n=498) 
Recognized 
dementia 
(n=517) 
Demographics     
Age in years, mean (SD) 80.1 (6.6)  79.7 (6.5) 85.4 (6.0) 85.0 (6.2) 
Female 10,044 (60) 9,417 (60) 304 (61) 323 (62) 
Medical diagnoses, past 2 years 
Congestive heart failure 2,127 (13) 1,840 (12) 138 (28) 149 (29) 
Cerebrovascular disease 2,028 (12) 1,726 (11) 107 (21) 195 (38) 
Diabetes, any 2,425 (15) 2,243 (14) 99 (20) 83 (16) 
Diabetes, complex 1,205 (7) 1,090 (7) 63 (13) 52 (10) 
Chronic pulmonary disease 3,140 (19) 2,919 (19) 94 (19) 127 (25) 
Hypothyroidism 2,237 (13) 2,026 (13) 95 (19) 116 (22) 
Renal failure 1,761 (11) 1,587 (10) 67 (13) 107 (21) 
Lymphoma 183 (1) 167 (1) 7 (1) 9 (2) 
Solid tumor w/o metastases 3,894 (23) 3,656 (23) 99 (20) 139 (27) 
Rheumatoid arthritis 953 (6) 877 (6) 26 (5) 50 (10) 
Weight loss 116 (1) 91 (1) 3 (1) 22 (4) 
Fluid and electrolyte disorders 2,215 (13) 1,914 (12) 99 (20) 202 (39) 
Blood loss anemia 737 (4) 661 (4) 30 (6) 46 (9) 
Psychoses 471 (3) 308 (2) 35 (7) 128 (24) 
Depression 2,573 (15) 2,235 (14) 129 (26) 209 (40) 
Traumatic brain injury 252 (2) 211 (1) 22 (4) 19 (4) 
Tobacco use disorder 1,213 (7) 1,132 (7) 24 (5) 57 (11) 
Atrial fibrillation  2,513 (15) 2,260 (14) 117 (23) 136 (26) 
Gait abnormality  1,534 (9) 1,292 (8) 87 (17) 155 (30) 
Vital signs, most recent, past 3 years 
Underweight (BMI<18.5) 289 (2) 243 (2) 20 (4) 26 (5) 
Obese (BMI≥30) 3,625 (22) 3,478 (22) 72 (15) 75 (15) 
High BP (≥140 SBP or 90 DBP) 457 (3) 430 (3) 13 (3) 14 (3) 
Healthcare utilization, past 2 years 
≥1 outpatient visit 16,453 (99) 15,449 (99) 490 (98) 260 (99) 
≥1 emergency department visit  4,606 (28) 4,095 (26) 230 (46) 281 (54) 
≥1 home health visit 1,617 (10) 1,380 (9) 89 (18) 148 (29) 
≥1 physical therapy visit 6,293 (38) 5,902 (38) 181 (36) 210 (41) 
≥1 speech, language and 
learning visit 478 (3) 343 (2) 24 (5) 111 (21) 
Medication-related predictors, past 2 years 
Fill for non-TCA antidepressant  2,426 (15) 2,102 (12) 135 (26) 189 (35) 
Fill for sedative/hypnotic 4,472 (27) 4,144 (21) 150 (22) 178 (28) 
Additional predictors considered for full model 
≥1 clinic “no shows” 5,143 (31) 4,666 (30) 210 (42) 267 (52) 
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≥1 ACS hospitalizations 166 (1) 138 (1) 7 (1) 21 (4) 
≥1 ACS emergency visits 1,109 (7) 999 (6) 50 (10) 60 (12) 
Medication non-adherencea 2,928 (18) 2,662 (17) 131 (26) 135 (26) 
 *Values are number (%) or mean (standard deviation). For <1% of visits, no information on blood pressure or BMI 543 
was available in the preceding three years. In these cases, we imputed values for the missing data using fully 544 
conditional specification methods available in SAS, version 9.4 (SAS Institute, Inc., Cary, NC). ACS, ambulatory 545 
care sensitive; BMI, body mass index; DBP, diastolic blood pressure; TCA, tricyclic antidepressant; SBP, systolic 546 
blood pressure; SD, standard deviation. Table includes predictors retained in final models. See Supplementary Table 547 
S1 for prevalence of all predictors considered.  548 
adefined as <80 percent of days covered (PDC) for oral anti-diabetics, anti-hypertensives or statins 549 
  550 
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Table 2. Final Restricted and Full eRADAR Model Coefficients for Predicting Undiagnosed 551 
Dementia 552 
Predictor Restricted Model Full Model 
Intercept -11.83 -11.86 
Demographics   
Age (per year) 0.11 0.11 
Female -0.10 -0.07 
Diagnoses, past 2 years   
Congestive heart failure 0.28 0.23 
Cerebrovascular disease 0.18 0.16 
Diabetes, any 0.06  
Diabetes, complex 0.34 0.29 
Chronic pulmonary disease -0.11 -0.10 
Hypothyroidism 0.05 0.02 
Renal failure -0.15 -0.13 
Lymphoma 0.01  
Solid tumor without metastases -0.17 -0.16 
Rheumatoid arthritis -0.05 -0.01 
Weight loss -0.34 -0.31 
Fluid and electrolyte disorders -0.07 -0.06 
Blood loss anemia -0.25 -0.22 
Psychoses 0.46 0.43 
Depression 0.03  
Traumatic brain injury 0.20 0.17 
Tobacco use disorder -0.15 -0.12 
Atrial fibrillation  0.03 0.02 
Gait abnormality  0.24 0.20 
Vital signs, most recent, past 3 years   
Underweight (BMI < 18.5) 0.29 0.26 
Obese (BMI ≥ 30) -0.11 -0.09 
High blood pressure (≥140 SBP or ≥90 DBP) -0.09 -0.07 
Healthcare utilization, past 2 years   
≥1 outpatient visit -0.55 -0.53 
≥1 emergency department visit  0.34 0.30 
≥1 home health visit 0.00  
≥1 physical therapy visit -0.13 -0.14 
≥1 speech, language and learning visit 0.47 0.42 
Medications, past 2 years   
Fill for non-tricyclic antidepressant 0.58 0.55 
Fill for sedative-hypnotic 0.03  
Additional predictors considered for full model   
≥1 clinic “no show”  0.18 
≥1 ACS hospitalizations  0.10 
≥1 ACS emergency visits  -0.06 
Medication non-adherencea  0.29 
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Values reflect truncated coefficients from the final restricted and full models. Full coefficients 553 
are included in Supplementary Table S2. ACS, ambulatory care sensitive; BMI, body mass 554 
index; DBP, diastolic blood pressure; SBP, systolic blood pressure. 555 
adefined as <80% of days covered (PDC) for oral anti-diabetics, anti-hypertensives or statins   556 
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Table 3. Performance of Restricted Model Using Different Decision Rules 557 
Risk cut-off  
(percentile*) 
Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
≥ 99th 6.5 99.4 23.7 97.2 
≥ 95th 22.5 96.4 15.7 97.6 
≥ 90th 36.2 91.6 11.5 97.9 
≥ 85th 47.1 87.2 10.0 98.2 
≥ 80th 59.4 82.9 9.5 98.5 
≥ 75th 65.9 78.0 8.3 98.7 
≥ 70th 72.5 72.9 7.5 98.9 
≥ 65th 79.0 67.5 6.8 99.1 
≥ 60th 83.3 62.6 6.3 99.2 
≥ 55th 87.7 56.9 5.8 99.4 
≥ 50th 91.3 51.9 5.4 99.5 
NPV, negative predictive value; PPV, positive predictive value 558 
*Percentile of the predicted risk distribution observed in the training sample. Performance 559 
characteristics are then shown in the test sample when using the given risk cut-off for classifying 560 
as unrecognized dementia. Values for the model that considered the full set of predictors are 561 
included in Supplementary Table S3.  562 
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Supplementary Material for Development and Validation of eRADAR: A Tool Using EHR Data to Detect 
Unrecognized Dementia 
 
 The purpose of this online supplement is to provide additional details of the full and restricted electronic 
health record (EHR) Risk of Alzheimer’s and Dementia Assessment Rule (eRADAR) models. As described in the 
main manuscript, eRADAR was developed as a tool that uses EHR data to help detect patients with unrecognized 
dementia. The full model included some predictors that might be challenging to extract in some healthcare systems, 
such as low medication adherence, missed clinic visits and hospitalizations for ambulatory care sensitive (ACS) 
conditions. The main manuscript includes prevalence data for a restricted set of predictors considered (Table 1), 
truncated coefficients for the restricted and full models (Table 2), and performance results for the restricted model 
(Table 3, Figure 2). This supplement provides more detailed results for the full and restricted models.  
 
Supplementary Table S1 provides the prevalence of all EHR predictors considered by visit status.  
 
Supplementary Table S2 provides the full coefficients for the variables retained in the full and restricted 
models.  
 
Supplementary Table S3 provides model performance statistics for different decision rules in the full 
model. 
 
Supplementary Figure S1 provides discrimination and calibration plots for the full model. 
 
 
  
Supplementary Table S1. Prevalence of Electronic Health Record (EHR) Predictors by Visit Status 
 
EHR Predictors 
All visits 
(N = 16,655) 
No 
dementia 
(N = 15,640) 
Unrecognized 
dementia 
(N = 498) 
Recognized 
dementia 
(N = 517) 
Demographics       
Age in years, mean (SD) 80.1 (6.6) 79.7 (6.5) 85.4 (6.0) 85.0 (6.2) 
Female 10,044 (60) 9,417 (60) 304 (61) 323 (62) 
Non-Hispanic white 14,974 (90) 14,055 (90) 451 (91) 468 (91) 
         
Medical diagnoses, past 2 years        
Hypertension, any 8,520 (51) 7,898 (50) 289 (58) 333 (64) 
Hypertension, complex 188 (1) 174 (1) 4 (1) 10 (2) 
Myocardial infarction 1,508 (9) 1,352 (9) 64 (13) 92 (18) 
Congestive heart failure 2,127 (13) 1,840 (12) 138 (28) 149 (29) 
Peripheral vascular disease 1,684 (10) 1,496 (10) 65 (13) 123 (24) 
Cerebrovascular disease 2,028 (12) 1,726 (11) 107 (21) 195 (38) 
Diabetes, any 2,425 (15) 2,243 (14) 99 (20) 83 (16) 
Diabetes, complex 1,205 (7) 1,090 (7) 63 (13) 52 (10) 
Chronic obstructive pulmonary disease 3,140 (19) 2,919 (19) 94 (19) 127 (25) 
Hypothyroidism 2,237 (13) 2,026 (13) 95 (19) 116 (22) 
Renal failure 1,761 (11) 1,587 (10) 67 (13) 107 (21) 
Liver disease 196 (1) 186 (1) 6 (1) 4 (1) 
Lymphoma 183 (1) 167 (1) 7 (1) 9 (2) 
Solid tumor without metastases  3,894 (23) 3,656 (23) 99 (20) 139 (27) 
Metastatic cancer 382 (2) 356 (2) 9 (2) 17 (3) 
Rheumatoid arthritis 953 (6) 877 (6) 26 (5) 50 (10) 
Obesity  1,117 (7) 1,070 (7) 21 (4) 26 (5) 
Weight loss 116 (1) 91 (1) 3 (1) 22 (4) 
Fluid and electrolyte disorders 2,215 (13) 1,914 (12) 99 (20) 202 (39) 
Blood loss anemia 737 (4) 661 (4) 30 (6) 46 (9) 
Deficiency anemias 2,245 (13) 1,982 (13) 96 (19) 167 (32) 
Alcohol dependence/abuse 225 (1) 195 (1) 8 (2) 22 (4) 
Psychoses 471 (3) 308 (2) 35 (7) 128 (24) 
Depression 2,573 (15) 2,235 (14) 129 (26) 209 (40) 
Anxiety 1,455 (9) 1,282 (8) 58 (12) 115 (22) 
Traumatic brain injury 252 (2) 211 (1) 22 (4) 19 (4) 
Tobacco use disorder  1,213 (7) 1,132 (7) 24 (5) 57 (11) 
Atrial fibrillation 2,513 (15) 2,260 (14) 117 (23) 136 (26) 
Gait abnormality 1,534 (9) 1,292 (8) 87 (17) 155 (30) 
Malaise and fatigue 2,972 (18) 2,616 (17) 132 (27) 224 (43) 
Snycope and collapse 1,226 (7) 1,059 (7) 59 (12) 108 (21) 
         
Vital signs, most recent, past 3 years        
Body Mass Index, kg/m2        
     Underweight (<18.5) 289 (2) 243 (2) 20 (4) 26 (5) 
     Normal (18.5-24.9) 5,996 (36) 5,551 (36) 207 (44) 238 (48) 
     Overweight (25.0-29.9) 6,609 (40) 6,281 (40) 175 (37) 153 (31) 
     Obese (≥30) 3,625 (22) 3,478 (22) 72 (15) 75 (15) 
          Missing 136 (1) 87 (1) 24 (5) 25 (5) 
Blood pressure, mm Hg        
     Low (≤90 SPB or ≤60 DBP) 2,397 (15) 2,218 (14) 87 (18) 92 (19) 
     Normal (90-139 SPB and 60-89 DBP) 7,506 (45) 7,080 (46) 218 (45) 208 (42) 
     High (140-180 SPB or 90-110 DBP) 6,174 (37) 5,834 (37) 162 (34) 178 (36) 
     Very high (>180 SBP or >110 DBP) 457 (3) 430 (3) 13 (3) 14 (3) 
          Missing 121 (1) 78 (1) 18 (4) 25 (5) 
         
Healthcare utilization, past 2 years        
Number of outpatient visits        
0 202 (1) 191 (1) 8 (2) 3 (1) 
1 – 4 3,231 (19) 3,123 (20) 75 (15) 33 (6) 
5 – 15 9,859 (59) 9,303 (59) 274 (55) 282 (55) 
16+ 3,363 (20) 3,023 (19) 141 (28) 199 (38) 
≥1 emergency department (ED) visit 4,606 (28) 4,095 (26) 230 (46) 281 (54) 
≥1 usual care visits 6,115 (37) 5,627 (36) 194 (39) 294 (57) 
≥1 hospitalization 3,651 (22) 3,252 (21) 156 (31) 243 (47) 
≥1 visit or hospitalization for accident/injury 6,201 (37) 5,710 (37) 216 (43) 275 (53) 
≥1 for social work 925 (6) 753 (5) 46 (9) 126 (24) 
≥1 for home health 1,617 (10) 1,380 (9) 89 (18) 148 (29) 
≥1 for physical therapy 6,293 (38) 5,902 (38) 181 (36) 210 (41) 
≥1 for mental health 1,116 (7) 982 (6) 45 (9) 89 (17) 
≥1 for speech/language evaluation 478 (3) 343 (2) 24 (5) 111 (21) 
≥1 for neurology 1,557 (9) 1,385 (9) 55 (11) 117 (23) 
         
Medication-related predictors, past 2 years        
At least 1 fill for non-tricyclic anti-depressant 2,426 (15) 2,102 (12) 135 (26) 189 (35) 
At least 1 fill for tricyclic anti-depressant 2,084 (13) 1,948 (10) 70 (12) 66 (10) 
At least 1 fill for sleep aids 4,472 (27) 4,144 (21) 150 (22) 178 (28) 
         
Additional predictors considered for full 
model        
≥1 hospitalization for ACS condition 166 (1) 138 (1) 7 (1) 21 (4) 
≥1 ED visit for ACS condition 1,109 (7) 999 (6) 50 (10) 60 (12) 
Number of "No-shows"        
0 11,512 (69) 10,974 (70) 288 (58) 250 (48) 
1 3,208 (19) 2,955 (19) 118 (24) 135 (26) 
2+ 1,935 (12) 1,711 (11) 92 (18) 132 (26) 
Non-adherent to oral antidiabetic medications 
(PDC<0.8) 349 (2) 309 (2) 20 (4) 20 (4) 
Non-adherent to antihypertensive medications 
(PDC<0.8) 1,834 (11) 1,666 (11) 83 (17) 85 (16) 
Non-adherent to statin medications (PDC<0.8) 1,137 (7) 1,026 (7) 52 (10) 59 (11) 
Non-adherent to any of the above (PDC<0.8) 2,928 (18) 2,662 (17) 131 (26) 135 (26) 
*Values are number (%) or mean (standard deviation). For <1% of visits, no information on blood pressure or BMI 
was available in the preceding three years. In these cases, we imputed values for the missing data using fully 
conditional specification methods available in SAS, version 9.4 (SAS Institute, Inc., Cary, NC). ACS, ambulatory 
care sensitive; DBP, diastolic blood pressure; PDC, proportion of days covered; SBP, systolic blood pressure; SD, 
standard deviation. 
  
Supplementary Table s2. Final Restricted and Full eRADAR Model Coefficients for Predicting Undiagnosed 
Dementia 
 
Predictor Restricted Model Full Model 
Intercept -11.830350000 -11.85812969 
Demographics   
Age (per year) 0.106752900 0.10571371 
Female -0.100388300 -0.06622005 
Diagnoses, past 2 years   
Congestive heart failure 0.276673500 0.22783071 
Cerebrovascular disease 0.178279200 0.15900353 
Diabetes, any 0.055265100  
Diabetes, complex 0.342691800 0.2868975 
Chronic pulmonary disease -0.109553400 -0.09934154 
Hypothyroidism 0.047436960 0.02048503 
Renal failure -0.152401400 -0.13457552 
Lymphoma 0.008705084  
Solid tumor without metastases -0.174057100 -0.16344498 
Rheumatoid arthritis -0.047738630 -0.01167555 
Weight loss -0.335304000 -0.30595569 
Fluid and electrolyte disorders -0.069815440 -0.05811336 
Blood loss anemia -0.245432800 -0.22324498 
Psychoses 0.455663800 0.43208578 
Depression 0.029791080  
Traumatic brain injury 0.203585400 0.16716438 
Tobacco use disorder -0.153738700 -0.12327459 
Atrial fibrillation  0.025268110 0.01789309 
Gait abnormality  0.237453600 0.2005278 
Vital signs, most recent, past 3 years   
Underweight (BMI < 18.5) 0.292162700 0.25846802 
Obese (BMI ≥ 30) -0.109842000 -0.08931627 
High blood pressure (≥140 SBP or ≥90 DBP) -0.085098810 -0.06604747 
Healthcare utilization, past 2 years   
≥1 outpatient visit -0.554316200 -0.53309893 
≥1 emergency department visit  0.339823400 0.2956018 
≥1 home health visit 0.000039779  
≥1 physical therapy visit -0.130691300 -0.13637517 
≥1 speech, language and learning visit 0.466184400 0.41995111 
Medications, past 2 years   
Fill for non-tricyclic anti-depressant 0.576963400 0.55111792 
Fill for sedative-hypnotic 0.026758060  
Additional predictors considered for full model   
≥1 clinic “no show”  0.17656019 
≥1 ACS hospitalizations  0.10458543 
≥1 ACS emergency visits  -0.06114821 
Medication non-adherencea  0.28809356 
Model Performance   
c-statistic (95% CI), training sample 0.78 (0.76, 0.80) 0.79 (0.77, 0.81) 
c-statistic (95% CI), test sample 0.81 (0.78, 0.84) 0.81 (0.77, 0.84) 
ACS, ambulatory care sensitive; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure;  
SBP, systolic blood pressure; TCA, tricyclic anti-depressant. 
adefined as <80% of days covered (PDC) for oral anti-diabetics, anti-hypertensives or statins. 
 
  
Supplementary Table S3. Performance of Full Model Using Different Decision Rules 
 
Risk cutoff 
(percentile*) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
≥ 99th 5.8 99.4 23.5 97.2 
≥ 95th 22.5 96.3 15.5 97.6 
≥ 90th 38.4 91.7 12.3 98.0 
≥ 85th 44.9 87.4 9.7 98.1 
≥ 80th 58.7 82.8 9.4 98.5 
≥ 75th 68.1 77.7 8.5 98.8 
≥ 70th 71.7 72.9 7.4 98.8 
≥ 65th 79.0 68.2 7.0 99.1 
≥ 60th 83.3 62.2 6.2 99.2 
≥ 55th 86.2 57.1 5.7 99.3 
≥ 50th 90.6 51.6 5.3 99.5 
NPV, negative predictive value; PPV, positive predictive value 
*Percentile of the predicted risk distribution observed in the training sample. Performance 
characteristics are then shown in the test sample when using the given risk cut-off for classifying 
as unrecognized dementia.   
eFigure1. Full eRADAR Model Performance 
 
eFigure 1a. Discrimination plot 
 
eFigure 1b. Calibration plot 
 
 
 

